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Abstract
Pertussis is a common vaccine-preventable disease (VPD) worldwide. Its reported incidence has 
increased steadily in the United States, where it is endemic. Tetanus is a rare but potentially fatal 
VPD. Foreign-born adults have lower tetanus–diphtheria–pertussis (Tdap) and tetanus–diphtheria 
(Td) vaccination coverage than do U.S.-born adults. We studied the association of migration-
related, socio-demographic, and access-to-care factors with Tdap and Td vaccination among 
foreign-born adults living in the United States. The 2012 and 2013 National Health Interview 
Survey data for foreign-born respondents were analyzed. Multivariable logistic regression was 
conducted to calculate prevalence ratios and 95% confidence intervals, and to identify variables 
independently associated with Tdap and Td vaccination among foreign-born adults. Tdap and Td 
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vaccination status was available for 9316 and 12,363 individuals, respectively. Overall vaccination 
coverage was 9.1% for Tdap and 49.8% for Td. Younger age, higher education, having private 
health insurance (vs. public insurance or uninsured), having visited a doctor in the previous year, 
and region of residence were independently associated with Tdap and Td vaccination. Among 
those reporting a doctor visit, two-thirds had not received Tdap. This study provides further 
evidence of the need to enhance access to health care and immunization services and reduce 
missed opportunities for Tdap and Td vaccination for foreign-born adults in the United States. 
These findings apply to all foreign-born, irrespective of their birthplace, citizenship, language and 
years of residence in the United States. Addressing vaccination disparities among the foreign-born 
will help achieve national vaccination goals and protect all communities in the United States.
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Introduction
Pertussis, among the most common vaccine-preventable diseases (VPD) worldwide [1], is 
endemic in the United States, with an average of approximately 23,000 cases reported 
annually during the past decade [2]. The number of cases increased to more than 48,000 in 
2012, the most reported since 1955, and included 20 related deaths [3]. In 2014, the state of 
California experienced an epidemic with 11,000 cases and 3 infant deaths [4, 5].
Although considered a childhood disease, pertussis incidence among adults has increased 
steadily, with one-fifth of U.S. cases reported in 2013 in persons >20 years old [6]. This rise 
in the incidence has been attributed to improved awareness among healthcare providers, 
availability of polymerase chain reaction (PCR) as a diagnostic method, and improved 
surveillance and case reporting. Infected adults are an important source for pertussis 
transmission to infants and children who are too young to be vaccinated or have not received 
vaccination for another reason [7–9]; up to 55% of cases in infants have been attributed to 
adult family members [10].
Tetanus is a potentially fatal VPD that has become rare in the United States (26 cases 
reported in 2013) [11]. Most (90%) cases reported from 2001 to 2008 occurred in adults ≥20 
years of age. The case-fatality rate was 13%. Of case-patients with known vaccination status, 
40% had received no tetanus vaccine [12].
The Advisory Committee on Immunization Practices (ACIP) currently recommends a single 
tetanus, diphtheria, acellular pertussis (Tdap) dose for all adults aged 19 and older [13] and a 
dose of Tdap for women during each pregnancy, preferably during the third trimester, to 
provide passive newborn immunity via maternal antibodies. For non-pregnant adults, tetanus 
and diphtheria toxoid (Td) boosters without the pertussis component should be administered 
every 10 years after the previous tetanus toxoid-containing vaccine [13].
Tdap vaccination coverage among all adults aged ≥19 years in the United States is low (14% 
in 2012 and 17% in 2013) [14, 15]. The proportion of all adults aged ≥18 years reporting 
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having received any tetanus toxoid-containing vaccination (either Tdap or Td) was higher 
(62%) in 2012 [16], but has not increased substantially since 1999 [17]. Vaccination levels 
are generally lower among racial and ethnic minorities compared with non-Hispanic Whites 
[14, 18]. A recent study using 2012 National Health Interview Survey (NHIS) data identified 
significant disparities for Tdap and Td vaccination between foreign-born adults and the 
U.S.-born population [16]. These findings have high public health relevance because the 
foreign-born constitute an increasing share of the U.S. population (13% in 2013; expected to 
be 18% by 2050) [19–21]. Most immigrants come from countries with different 
immunization schedules and access to vaccines compared with the United States [22]. For 
Tdap and Td adult vaccination, most countries other than the United States only target 
specific sub-populations (e.g., healthcare providers, pregnant women, and other high-risk 
groups) [23–25]. The foreign-born also experience barriers to accessing healthcare and 
preventive services once they have migrated [16].
In a previous study, vaccination disparities among the foreign-born remained after adjusting 
for relevant sociodemographic and access-to-care characteristics [16]. However, the 
individual effects of those variables and of specific migration-related factors (e.g., 
birthplace, citizenship, language and years in the United States) on Tdap and Td vaccination 
coverage was explored only through bivariate analysis. Our study was restricted to foreign-
born participants. We used data from the 2012 and 2013 NHIS to identify 
sociodemographic, access-to-care, and migration-related characteristics that are 
independently associated with Tdap and Td vaccination among foreign-born adults living in 
the United States. Immunization programs and vaccine providers can use this information 
when developing strategies and interventions to eliminate disparities in coverage.
Methods
Study Design, Setting, and Population
This study was restricted to the foreign-born participants in the 2012 and 2013 NHIS. The 
NHIS is an annual household cross-sectional survey conducted by the CDC’s National 
Center for Health Statistics, which collects health information on the U.S. civilian, non-
institutionalized population [26]. In the sample adult core, one adult per sampled family in 
each household was randomly selected to complete questions about vaccination history. The 
final response proportion for the sample adult core was 61.2% in both 2012 and 2013 [26]. 
The NHIS has routinely collected Tdap/Td vaccination information since 2008 through a 
series of three questions. Respondents are first asked, “Have you received a tetanus shot in 
the past 10 years?” If respondents answer “yes” they are asked, “Was your most recent 
tetanus shot given in 2005 or later?” Respondents who answer “yes” to this question are then 
asked, “Thinking back to your most recent tetanus shot, did your healthcare provider tell 
you, or did the vaccine information sheet say, the vaccine included the pertussis or whooping 
cough vaccine?” Among 13,154 foreign-born respondents ≥18 years, those without a “yes” 
or “no” classification for tetanus vaccination status within the preceding 10 years (n = 791 
[6.0%]) were excluded from the Td analysis, yielding a sample of 12,363 for whom Td 
vaccination status could be assessed. Those without a “yes” or “no” classification for tetanus 
vaccination status during 2005–2013 [n = 349 (2.7%)], those who reported tetanus 
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vaccination during 2005–2013 but were not told vaccine type by the provider [n = 2222 
(16.9%)], or those who did not know vaccine type (Tdap or Td) [n = 476 (3.6%)] were 
excluded, yielding a sample of 9316 respondents ≥18 years for whom Tdap vaccination 
status could be assessed.
Exposures, Outcomes, Covariates
Outcomes of interest were Tdap vaccination (Tdap vaccine received at any time since 2005) 
and Td vaccination (Td vaccine received in the previous 10 years). Exposures of interest 
included migration-related factors (birthplace, duration of residence in the United States, 
U.S. citizenship status, language of interview), and healthcare access-related factors (health 
insurance status, number of doctor visits in the past year, whether the respondent had a usual 
source of healthcare). For statistical stability and to preserve confidentiality, countries of 
birth were grouped into five regions in the analysis: Mexico/Central America/Caribbean 
Islands, South America, Europe, Asia, and Other. Covariates to measure associations with 
vaccination coverage included: age, sex, race/ethnicity, marital status, living with an infant 
age <1 year, education, employment status, poverty level, self-reported health status, and 
region of U.S. residence. Poverty status was defined using U.S. Census Bureau poverty 
thresholds, with “below poverty” defined as total family income of <$23,492 or <$23,834 
for a family of four in 2012 and 2013, respectively [27].
Statistical Analysis
SUDAAN statistical software (Research Triangle Institute, Research Triangle Park, NC) was 
used to calculate weighted point estimates and 95% confidence intervals (CI) of vaccination 
coverage [28]. Multivariable logistic regression and predictive marginal modeling were used 
to generate adjusted prevalence ratios and identify variables independently associated with 
Tdap and Td vaccination. Sensitivity analyses were conducted to assess the magnitude of 
potential bias resulting from respondent exclusions, assuming those who answered that they 
received a tetanus shot but were not sure what type had either received Tdap vaccine or did 
not receive Tdap vaccine. Statistical significance was defined as p < 0.05. The NHIS was 
approved by the Research Ethics Review Board (ERB number 2009–16) of the National 
Center for Health Statistics, CDC.
Results
Of 13,154 foreign-born participants in the 2012 and 2013 NHIS, 9316 were included in the 
analysis for Tdap and 12,363 in the analysis for Td. The sociodemographic, access-to-care, 
and migration-related characteristics of the study population are presented in Table 1. Most 
participants were aged 18–49 years (64.0%), female (51.3%), Hispanic (49.5%), married 
(62.6%), had high school or higher education (71.8%), and were employed (64.1%). Most 
had health insurance (68.4%), reported having visited a doctor at least once during the 
previous year (69.9%), and reported having a usual source for healthcare (74.5%). Most of 
the subjects had been in the United States for at least 10 years (79.3%) and were U.S. 
citizens (53%). An interview language other than English was reported by 30.7%. Birthplace 
was Mexico/Central America/Caribbean (48.2%), Asia (23.2%), Europe (12.5%), and South 
America (6.2%).
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Vaccination coverage for Td (overall 49.8%) was consistently higher than that for Tdap 
(overall 9.1%) among all subpopulations (Table 2). Depending on what proportion of 
excluded respondents actually received Tdap, the sensitivity analysis suggested actual Tdap 
coverage within the range of 7.0–30.1%.
In bivariate analysis (Table 2), coverage for both vaccines was significantly lower among 
Hispanics (6.5% for Tdap and 48.4% for Td) than among non-Hispanic whites (10.5% for 
Tdap and 54.7% for Td), and lower among people living below poverty (5.6% for Tdap and 
42.5% for Td) than among those living at or above poverty (10.7% for Tdap and 52.6% for 
Td). Significantly higher coverage for both vaccines was associated with completing at least 
some college education, having private health insurance, and having a usual source of 
healthcare (Table 2). Coverage was higher for those reporting at least one doctor visit in the 
previous year. However, additional analysis (data not shown) indicated that a large 
proportion (66.3%) of those who had not received Tdap reported one or more doctor visits 
during the previous year. Among those with 10 or more doctor visits in the previous year, 
coverage was 13.4% (95% CI, 10.7%, 16.5%) for Tdap and 56.1% (95% CI, 52.4%, 59.6%) 
for Td. Among adults who had not received Tdap, 65.5% had either private insurance 
(43.5%) or had public insurance (22.0%) (data not shown).
Significantly lower coverage for both vaccines was found among those reporting to be non-
U.S. citizens and those interviewed in a language other than English. Individuals born in 
Mexico, Central America, or Caribbean Islands had the lowest Tdap and Td vaccination 
coverage compared with other birth regions (Table 2). Foreign-born persons residing in the 
United States for ≥10 years had significantly lower vaccination coverage for Tdap compared 
with more recent arrivals (≤5 years) (Table 2).
In multivariable analysis, characteristics independently associated with an increased 
likelihood of Tdap and Td vaccination among foreign-born adults were younger age, higher 
education, having private insurance, and reporting having had at least one visit with a doctor 
in the previous year, with a trend towards an increased prevalence ratio for vaccination with 
increasing number of visits (Table 3). Individuals living in the Northeast region were less 
likely to have received Td when compared with all other regions, and were less likely to 
have received Tdap when compared with the Midwest and West regions, but not with the 
South region (Table 3).
Discussion
Adult vaccination in the United States remains low for most recommended vaccines, 
including Tdap and Td, and continues to be a public health challenge [14, 15]. For Tdap, 
coverage remains low despite recommendations since 2005 that included all adults up to age 
64 and since 2012 all adults aged ≥19 years [13], as well as strategies targeting adults who 
have close contact with newborns (i.e., “cocooning”) [14, 15, 29]. For Td, a booster every 10 
years has been recommended for all adults for more than 20 years [30], but low coverage 
persists. Reasons for low adult vaccination coverage include limitations of the adult 
vaccination delivery system and physician-related barriers (e.g., not routinely administering 
indicated vaccines during patient visits) [31]. Several socioeconomic and access-to-care 
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factors (e.g., race/ethnicity, older age, lower education and income, lack of health insurance, 
access to care, and region of residence in the United States) have been independently 
associated with lower likelihood of Tdap and Td vaccination among U.S. adults [18]. For the 
foreign-born, vaccination coverage has been reported to be affected by birthplace, 
citizenship, language spoken, and years of residence in the United States [16].
In this study, we explored the effect of migration-related factors on vaccination coverage 
when analyzed together with relevant sociodemographic and access-to-care characteristics. 
Our findings indicate that for foreign-born adults, the primary factors independently 
associated with Tdap and Td vaccination are similar to those reported for the general U.S. 
population: age, education level, poverty (for Td vaccination only), healthcare access, and 
region of residence in the United States.
After controlling for all other variables in the multi-variable model, migration-related factors 
(i.e., birthplace, citizenship, language of the interview, duration of residence) did not 
significantly affect the likelihood of having received Tdap or Td vaccinations among the 
foreign-born. These findings suggest that strategies to address barriers to Tdap and Td 
vaccination are needed for all in the foreign-born population, irrespective of migration-
related factors, and are similar to those needed in the general U.S. born population.
Adults <50 years old were more likely to be vaccinated with Tdap and Td than older adults, 
a finding also reported for sub-populations in the United States such as healthcare providers 
and parents of children and adolescents [29, 32]. Younger adults may be better informed 
about vaccines, exposed to college campus prevention programs and vaccine requirements 
for enrollment, vaccinated in adolescent programs, or have more contact with healthcare 
providers through their young children. Recall bias could also partially explain this 
difference, with older adults having problems remembering receipt of vaccines that are 
scheduled in 10-year intervals.
We found a trend toward higher prevalence of Tdap and Td vaccination with higher levels of 
education, similar to trends seen for several vaccines among more highly educated 
populations in the United States [33–35]. The association between education and vaccination 
status might be related to greater vaccine and disease awareness. A physician’s or other 
healthcare provider’s recommendation has been shown to be a powerful determinant for 
adults to receive vaccinations [29], although such recommendations are provided 
inconsistently [33]. Higher educational attainment might make an adult more knowledgeable 
about vaccine recommendations and more willing to ask the health-care provider to provide 
them.
Individuals living below poverty level were significantly less likely to have received Td 
vaccine. Financial barriers have been reported previously as a factor associated with 
suboptimal vaccination coverage among pregnant women, Latinos, and rural adults in the 
United States [34–37].
In our study, individuals who had public health insurance or were uninsured were less likely 
to be vaccinated with Tdap and Td than were those with private health insurance. In 2012, 
Singer et al. also reported higher Tdap vaccination coverage among adults with private 
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health insurance plans [38]. Provider reimbursement might be an important factor, as 
primary care physicians have reported dissatisfaction with payments for vaccine purchase 
and payments by third-party payers, especially payers for public health insurance [39]. With 
the introduction of the Patient Protection and Affordable Care Act (ACA) in 2010, all new 
health insurance plans are required to include ACIP-recommended vaccines for adults in 
their covered services without charging any fee [40]. The effect of the ACA on vaccination 
coverage among adults, particularly among the foreign-born, has yet to be determined.
Having one or more doctor visits in the year prior to the interview was significantly 
associated with greater Tdap and Td vaccination coverage when compared with individuals 
lacking such visits; this association strengthened with higher number of visits. Although 
similar findings have been reported for the overall U.S. adult population [18], our study 
demonstrated that coverage remains suboptimal even with repeated health encounters. These 
findings, along with the lower Tdap and Td vaccination coverage among those with public 
health insurance, and the high proportion (86.7%) of privately insured foreign-born adults 
who had not received Tdap, strongly suggest that substantial opportunities for vaccination 
are missed in this population, particularly for public insurance holders.
Additional reasons for low vaccination levels among adults have been reported for the 
general U.S. population, including limited knowledge about VPD risks and adult vaccination 
recommendations and negative beliefs about the efficacy and safety of vaccines [29, 33, 41]; 
however, information about the knowledge and beliefs of respondents regarding VPDs and 
vaccines was not available for this study. Further research is needed to characterize 
knowledge and attitudes about vaccines among the foreign-born population, as well as 
potential differences by subpopulations (e.g., by country of origin, education, acculturation).
The findings in this study are subject to at least three limitations. First, vaccination status 
was self-reported and might be subject to recall bias. However, self-reported tetanus 
vaccination has been shown to be sensitive, but not specific, suggesting that coverage 
estimates are more likely to be erroneously high than low [42]. Second, the Tdap estimates 
are subject to considerable uncertainty because respondents who reported a tetanus 
vaccination, but were unable to say whether Tdap or Td was used, were excluded from the 
estimations of Tdap coverage, creating a potential for bias. Although sensitivity analyses 
showed a wide range for Tdap estimates depending on what proportion of excluded 
respondents might actually have received Tdap and coverage could be underestimated, the 
upper limit (30.1%) is still suboptimal. Language of the interview might not be a good proxy 
for primary language of the respondent or English-speaking ability, variables that are easier 
to interpret and for which there is greater evidence of their effect on access-to-care and 
receipt of prevention services. Finally, birthplace was available only by region, so 
determination of the impact of actual country of birth was not possible.
Factors associated with low Tdap and Td vaccination coverage among foreign-born adults in 
this study were primarily related to education, access to care (including type of health 
insurance) and failure to utilize existing opportunities to vaccinate. Thus, strategies are 
needed to enhance access to health insurance and vaccination services for foreign-born 
individuals, and to utilize all opportunities to vaccinate when they do contact the health 
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system, especially in public health insurance settings. A systems approach including 
adequate reimbursement, standing vaccination orders not requiring physician involvement, 
and patient and provider education has proven to be effective in enhancing adult vaccination 
[43, 44]. Strategies should also target healthy adult foreign-born individuals who have little 
contact with healthcare providers, and include vaccinations in nontraditional settings (e.g., 
churches, pharmacies, and workplaces) in localities with high concentration of foreign-born 
residents. Culturally and linguistically appropriate education and outreach to these 
populations are also needed [30]. Since most foreign-born are of Latino or Asian origin [45], 
addressing vaccination in these populations would have the greatest impact on reducing 
racial and ethnic disparities, reaching national vaccination goals, and protecting everyone in 
the United States.
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Table 1
Sociodemographic and health access characteristics of foreign-born adults ≥18 years of age, National Health 
Interview Survey (NHIS), 2012–2013, United States
Characteristic N Weighted %
Total 13,154 100.0
Age
 18–49 years    8193   64.0
 50–64 years    2835   22.9
 65+ years    2126   13.1
Sex
 Male    5976   48.7
 Female    7178   51.3
Race/ethnicity
 Non-Hispanic white    1867   19.3
 Non-Hispanic black    1016    7.5
 Hispanic    7013   49.5
 Non-Hispanic other    3258   23.7
Marital status
 Married    6963   62.6
 Widowed/divorced/separated    2807   14.1
 Never married    3351   23.3
Living with an infant aged <1year
 Yes      575    4.9
 No 12,579   95.1
Education
 Less than high school    4097   28.2
 High school graduate    2782   22.2
 Some college    1610   12.8
 Associate degree    1014    8.0
 Bachelor’s degree or higher    3526   28.8
Employment status
 Employed    8115   64.1
 Unemployed      791    6.0
 Not in work force    4239   29.9
Poverty levela
 At or above poverty    8739   78.8
 Below poverty    3195   21.2
Health insurance
 Yes, private    5665   47.4
 Yes, public    3233   21.0
 Not insured    4218   31.5
Number of doctor visits in past year
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Characteristic N Weighted %
 0    3943   30.1
 1    2357   19.1
 2–3    2943   23.5
 4–9    2503   18.5
 10+    1194    8.8
Usual source of care
 Yes    9633   74.5
 No    3420   25.5
Self-reported health status
 Excellent/very good    7378   58.8
 Good    3818   28.2
 Fair    1544   10.2
 Poor      407    2.8
Duration of residence
 In U.S. <5 years    1162    8.4
 In U.S. 5 to <10 years    1574   12.3
 In U.S. ≥10 years 10,283   79.3
Citizenship
 U.S. citizen    6698   53.0
 Not U.S. citizen    6392   47.0
Language of the interview
 English    8673   69.3
 Not English    4481   30.7
Birthplace
 Mexico/Central America/Caribbean Islands    6804   48.2
 South America      827    6.2
 Europe    1235   12.5
 Asia    3160   23.2
 Others    1096    9.9
Region of U.S. residence
 Northeast    2568   21.2
 Midwest    1402   11.2
 South    4254   32.6
 West    4930   34.9
a
Poverty level as determined by Federal poverty guidelines
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Table 2
Tetanus, diphtheria and acellular pertussis (Tdap) or tetanus-diphtheria (Td) vaccination coverage among of 
foreign-born adults ≥18 years of age by sociodemographic and health access characteristics—National Health 
Interview Survey (NHIS), 2012–2013, United States
Tdap Td
% (95% CI) p value % (95% CI) p value
Total 9.1 (8.4–9.9) – 49.8 (48.7–51.0) –
Age
 18–49 yearsa 10.7 (9.7–11.7) – 51.4 (49.9–52.8) –
 50–64 years 7.1 (5.9–8.7)* <0.001 49.6 (47.1–52.2) 0.24
 65+ years 5.3 (3.7–7.4)* <0.001 42.5 (39.7–45.3)* <0.001
Sex
 Malea 8.0 (7.0–9.1) – 50.1 (48.3–51.9) –
 Female 10.2 (9.3–11.3)* <0.001 49.6 (48.0–51.1) 0.66
Race/ethnicity
 Non-Hispanic whitea 10.5 (8.5–12.8) – 54.7 (51.4–57.9) –
 Non-Hispanic black 11.7 (8.4–16.0) 0.60 50.1 (45.9–54.3) 0.07
 Hispanic 6.5 (5.7–7.5)* <0.001 48.4 (46.7–50.2)* <0.001
 Non-Hispanic other 12.6 (10.9–14.5) 0.16 48.6 (46.4–50.9)* <0.001
Marital status
 Marrieda 9.4 (8.5–10.5) – 51.4 (49.9–52.8) –
 Widowed/divorced/separated 6.5 (5.3–8.0)* <0.001 45.3 (42.9–47.6)* <0.001
 Never married 9.7 (8.2–11.4) 0.80 48.4 (46.0–50.7)* 0.03
Living with an infant aged <1 year
 Yesa 11.5 (8.4–15.7) – 50.0 (45.3–54.6) –
 No 9.0 (8.3–9.8) 0.19 49.8 (48.6–51.1) 0.96
Education
 Less than high schoola 4.8 (3.8–6.0) – 45.2 (43.1–47.3) –
 High school graduate 6.1 (4.9–7.7) 0.14 43.6 (41.1–46.1) 0.32
 Some college 9.2 (7.2–11.7)* <0.001 52.4 (48.9–55.8)* <0.001
 Associate degree 13.6 (10.8–16.9)* <0.001 56.2 (52.5–59.9)* <0.001
 Bachelor’s degree or higher 14.7 (13.2–16.3)* <0.001 56.6 (54.3–58.9)* <0.001
Employment status
 Employeda 9.9 (9.0–10.8) – 51.8 (50.4–53.2) –
 Unemployed 7.0 (4.9–10.0)* 0.04 46.7 (41.9–51.5)* 0.04
 Not in work force 8.0 (6.9–9.4)* 0.02 46.2 (44.1–48.2)* <0.001
Poverty level
 At or above povertya 10.7 (9.8–11.6) – 52.6 (51.3–54.0) –
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Tdap Td
% (95% CI) p value % (95% CI) p value
 Below poverty 5.6 (4.4–7.1)* <0.001 42.5 (40.1–45.0)* <0.001
Health insurance
 Yes, privatea 13.3 (12.1–14.6) – 56.9 (55.2–58.5) –
 Yes, public 6.0 (4.7–7.6)* <0.001 43.9 (41.3–46.6)* <0.001
 Not insured 5.5 (4.5–6.6)* <0.001 43.2 (41.3–45.1)* <0.001
Number of doctor visits in past year
 0a 5.1 (4.3–6.2) – 40.6 (38.5–42.6) –
 1 10.2 (8.5–12.2)* <0.001 53.5 (51.0–56.0)* <0.001
 2–3 10.6 (9.0–12.4)* <0.001 51.2 (48.9–53.5)* <0.001
 4–9 11.5 (9.8–13.3)* <0.001 56.7 (54.4–59.0)* <0.001
 10+ 13.4 (10.7–16.5)* <0.001 56.1 (52.4–59.6)* <0.001
Usual source of care
 Yesa 10.4 (9.5–11.2) – 52.6 (51.3–53.9) –
 No 5.9 (4.7–7.4)* <0.001 41.8 (39.5–44.2)* <0.001
Self-reported health status
 Excellent/very gooda 10.7 (9.7–11.8) – 51.2 (49.7–52.8) –
 Good 7.2 (6.1–8.5)* <0.001 48.1 (46.1–50.0)* 0.01
 Fair 6.5 (4.8–8.7)* <0.001 48.3 (44.7–52.0) 0.14
 Poor 4.9 (2.8–8.6)* <0.001 43.1 (36.4–50.1)* 0.02
Duration of residence
 In U.S. <5 yearsa 12.1 (9.1–16.0) – 50.7 (46.7–54.7) –
 In U.S. 5 to <10 years 11.5 (9.0–14.4) 0.75 51.8 (48.3–55.3) 0.66
 In U.S. ≥10 years 8.5 (7.7–9.3)* 0.04 49.4 (48.0–50.7) 0.55
Citizenship
 U.S. citizena 10.2 (9.2–11.2) – 51.9 (50.3–53.4) –
 Not U.S. citizen 8.0 (7.0–9.2)* 0.01 47.6 (45.8–49.3)* <0.001
Language of the interview
 Englisha 11.2 (10.3–12.2) – 51.9 (50.5–53.4) –
 Not English 4.6 (3.7–5.7)* <0.001 45.1 (43.0–47.2)* <0.001
Birthplace
 Mexico/Central America/Caribbean Islandsa 6.4 (5.6–7.4) – 48.0 (46.2–49.9) –
 South America 8.8 (6.3–12.2) 0.13 49.4 (45.3–53.5) 0.56
 Europe 10.5 (8.1–13.4)* <0.001 55.1 (51.5–58.6)* <0.001
 Asia 12.1 (10.4–14.0)* <0.001 49.1 (46.8–51.5) 0.51
 Others 13.9 (10.7–17.7)* <0.001 54.4 (49.7–59.1)* 0.02
Region of U.S. residence
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Tdap Td
% (95% CI) p value % (95% CI) p value
 Northeasta 7.0 (5.5–8.8) – 45.4 (43.3–47.6) –
 Midwest 12.7 (10.2–15.7)* <0.001 53.4 (49.8–56.9)* <0.001
 South 7.8 (6.7–9.0) 0.43 49.8 (47.9–51.8)* <0.001
 West 10.5 (9.4–11.8)* <0.001 51.4 (49.2–53.5)* <0.001
a
Reference level
*
P value by t test for comparisons for Tdap and Td within each level of each characteristic
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Table 3
Multivariable logistic regression and prevalence ratios of foreign-born adults ≥18 years of age who reported 
tetanus, diphtheria and acellular pertussis (Tdap) or tetanus-diphtheria (Td) vaccination, by socio-demographic 
and health access characteristics, National Health Interview Survey (NHIS) 2012–2013, United States
Tdap Td
Adjusted prevalence ratio (PR) 
(95% CI)
p value Adjusted prevalence ratio (PR) 
(95% CI)
p value
Age
 18–49 yearsa Referent – Referent –
 50–64 years 0.65 (0.52, 0.83)* <0.001 0.90 (0.84, 0.96)* <0.001
 65+ years 0.54 (0.34, 0.84)* <0.001 0.80 (0.73, 0.88)* <0.001
Sex
 Malea Referent – Referent –
 Female 1.15 (0.96, 1.38) 0.14 0.95 (0.90, 1.00) 0.07
Race/ethnicity
 Non-Hispanic whitea Referent – Referent –
 Non-Hispanic black 1.34 (0.82, 2.21) 0.26 0.97 (0.85, 1.12) 0.70
 Hispanic 1.23 (0.73, 2.08) 0.43 1.07 (0.93, 1.22) 0.33
 Non-Hispanic other 1.74 (1.00, 3.01) 0.07 0.88 (0.74, 1.05) 0.16
Marital status
 Marrieda Referent – Referent –
 Widowed/divorced/separated 0.91 (0.71, 1.16) 0.42 0.95 (0.89, 1.02) 0.14
 Never married 1.19 (0.96, 1.47) 0.12 1.01 (0.95, 1.07) 0.72
Living with an infant aged <1 year
 Yesa Referent – Referent –
 No 0.88 (0.63, 1.24) 0.49 0.99 (0.89, 1.10) 0.88
Education
 Less than high schoola Referent – Referent –
 High school graduate 1.06 (0.77, 1.45) 0.73 0.94 (0.87, 1.01) 0.09
 Some college 1.23 (0.84, 1.79) 0.29 1.06 (0.97, 1.16) 0.20
 Associate degree 1.84 (1.28, 2.63)* <0.001 1.17 (1.07, 1.27)* <0.001
 Bachelor’s degree or higher 1.71 (1.23, 2.38)* <0.001 1.12 (1.03, 1.23)* 0.01
Employment status
 Employeda Referent – Referent –
 Unemployed 0.76 (0.51, 1.12) 0.11 0.96 (0.86, 1.08) 0.51
 Not in work force 0.96 (0.77, 1.20) 0.71 0.97 (0.91, 1.03) 0.30
Poverty level
 At or above povertya Referent – Referent –
 Below poverty 0.82 (0.63, 1.09) 0.14 0.92 (0.87, 0.99)* 0.02
Health insurance
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Tdap Td
Adjusted prevalence ratio (PR) 
(95% CI)
p value Adjusted prevalence ratio (PR) 
(95% CI)
p value
 Yes, privatea Referent – Referent –
 Yes, public 0.67 (0.51, 0.88)* <0.001 0.85 (0.78, 0.92)* <0.001
 Not insured 0.73 (0.54, 0.97)* 0.02 0.88 (0.82, 0.95)* <0.001
Number of doctor visits in past year
 0a Referent – Referent –
 1 1.61 (1.20, 2.17)* <0.001 1.23 (1.14, 1.33)* <0.001
 2–3 1.74 (1.31, 2.31)* <0.001 1.18 (1.09, 1.29)* <0.001
 4–9 2.21 (1.67, 2.92)* <0.001 1.39 (1.28, 1.51)* <0.001
 10+ 2.74 (1.91, 3.94)* <0.001 1.40 (1.27, 1.55)* <0.001
Usual source of care
 Yesa Referent – Referent –
 No 0.89 (0.66, 1.19) 0.40 0.88 (0.82, 0.95)* <0.001
Self-reported health status
 Excellent/very gooda Referent – Referent –
 Good 0.88 (0.72, 1.09) 0.23 0.97 (0.92, 1.02) 0.26
 Fair 0.89 (0.63, 1.25) 0.46 1.00 (0.91, 1.09) 0.91
 Poor 0.88 (0.48, 1.63) 0.67 0.97 (0.84, 1.12) 0.67
Duration of residence
 In U.S. <5 yearsa Referent – Referent –
 In U.S. 5 to <10 years 1.06 (0.75, 1.50) 0.74 1.01 (0.91, 1.11) 0.87
 In U.S. ≥10 years 0.73 (0.53, 1.00) 0.09 0.92 (0.84, 1.00) 0.07
Citizenship
 U.S. citizena Referent – Referent –
 Not U.S. citizen 0.93 (0.75, 1.16) 0.52 0.96 (0.91, 1.02) 0.17
Language of the interview
 Englisha Referent – Referent –
 Not English 0.79 (0.59, 1.05) 0.08 1.00 (0.93, 1.07) 0.98
Birthplace
 Mexico/Central America/Caribbean Islanda Referent – Referent –
 South America 0.99 (0.69, 1.43) 0.98 0.95 (0.86, 1.05) 0.28
 Europe 1.02 (0.63, 1.64) 0.94 1.05 (0.92, 1.21) 0.48
 Asia 0.67 (0.38, 1.18) 0.16 1.01 (0.84, 1.21) 0.91
 Others 1.30 (0.86, 1.95) 0.22 1.09 (0.95, 1.23) 0.22
Region of U.S. residence
 Northeasta Referent – Referent –
 Midwest 1.56 (1.14, 2.15)* 0.01 1.16 (1.07, 1.25)* <0.001
 South 1.18 (0.90, 1.56) 0.22 1.09 (1.03, 1.16)* <0.001
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Tdap Td
Adjusted prevalence ratio (PR) 
(95% CI)
p value Adjusted prevalence ratio (PR) 
(95% CI)
p value
 West 1.64 (1.28, 2.10)* <0.001 1.12 (1.06, 1.20)* <0.001
a
Reference level
*
P value <0.05 by t test within each variable with the indicated reference level
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